Cargando…

Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors

Next-generation sequencing (NGS) has failed to detect mesenchymal epithelial transition factor gene (MET) polysomy in previous studies. We included three non–small cell lung cancer (NSCLC) cohorts in this retrospective study to establish new criteria for detecting MET polysomy and to explore the cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Boyang, Qiu, Tian, Zeng, Xiaoling, Duan, Jianchun, Bai, Hua, Xu, Jiachen, Li, Jin, Li, Junling, Hao, Xuezhi, Liu, Yutao, Lin, Lin, Wang, Hongyu, Zhang, Xin, Zhong, Jia, Wang, Jie, Ying, Jianming, Wang, Zhijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072163/
https://www.ncbi.nlm.nih.gov/pubmed/37025355
http://dx.doi.org/10.1158/2767-9764.CRC-22-0438
_version_ 1785019325733666816
author Sun, Boyang
Qiu, Tian
Zeng, Xiaoling
Duan, Jianchun
Bai, Hua
Xu, Jiachen
Li, Jin
Li, Junling
Hao, Xuezhi
Liu, Yutao
Lin, Lin
Wang, Hongyu
Zhang, Xin
Zhong, Jia
Wang, Jie
Ying, Jianming
Wang, Zhijie
author_facet Sun, Boyang
Qiu, Tian
Zeng, Xiaoling
Duan, Jianchun
Bai, Hua
Xu, Jiachen
Li, Jin
Li, Junling
Hao, Xuezhi
Liu, Yutao
Lin, Lin
Wang, Hongyu
Zhang, Xin
Zhong, Jia
Wang, Jie
Ying, Jianming
Wang, Zhijie
author_sort Sun, Boyang
collection PubMed
description Next-generation sequencing (NGS) has failed to detect mesenchymal epithelial transition factor gene (MET) polysomy in previous studies. We included three non–small cell lung cancer (NSCLC) cohorts in this retrospective study to establish new criteria for detecting MET polysomy and to explore the clinical relevance of MET polysomy. Cohort 1 included 53 patients whose tissues were available for both FISH and NGS assays. Paired plasma and tissue samples were obtained from 261 patients with NSCLC as cohort 2. Cohort 3 included 46 patients with metastatic NSCLC, who presented with MET copy-number gain assessed by NGS. ROC analysis demonstrated that a cut-off point of 2.3 copies achieved the maximum Youden index in discriminating polysomy from normal copy number. Compared with the FISH test for MET polysomy, the sensitivity, specificity, and agreement of NGS were 90%, 90%, and 96.2%, respectively. Following optimization using maximum somatic allele frequency, the sensitivity and specificity of NGS for defining polysomy using plasma samples according to different circulating tumor DNA mutation frequencies were 42% and 63%. The concordance rate between tissue and plasma samples for detecting polysomy was 85%. Regarding the response to MET inhibitor, the median progression-free survival (PFS) of the MET amplification group was significantly higher than that of the polysomy group. The median PFS was similar between the polysomy and normal groups. Our results indicated that NGS may serve as an alternative method for detecting MET polysomy in NSCLC tissues. Moreover, patients with MET polysomy may not benefit from MET inhibitors. SIGNIFICANCE: In this study, we established a methodology to differentiate polysomy from normal copy numbers and amplification using NGS. Moreover, this study suggests that it is critical to discriminate MET polysomy from amplification, for the former may dilute the clinical benefit of MET inhibitors.
format Online
Article
Text
id pubmed-10072163
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-100721632023-04-05 Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors Sun, Boyang Qiu, Tian Zeng, Xiaoling Duan, Jianchun Bai, Hua Xu, Jiachen Li, Jin Li, Junling Hao, Xuezhi Liu, Yutao Lin, Lin Wang, Hongyu Zhang, Xin Zhong, Jia Wang, Jie Ying, Jianming Wang, Zhijie Cancer Res Commun Research Article Next-generation sequencing (NGS) has failed to detect mesenchymal epithelial transition factor gene (MET) polysomy in previous studies. We included three non–small cell lung cancer (NSCLC) cohorts in this retrospective study to establish new criteria for detecting MET polysomy and to explore the clinical relevance of MET polysomy. Cohort 1 included 53 patients whose tissues were available for both FISH and NGS assays. Paired plasma and tissue samples were obtained from 261 patients with NSCLC as cohort 2. Cohort 3 included 46 patients with metastatic NSCLC, who presented with MET copy-number gain assessed by NGS. ROC analysis demonstrated that a cut-off point of 2.3 copies achieved the maximum Youden index in discriminating polysomy from normal copy number. Compared with the FISH test for MET polysomy, the sensitivity, specificity, and agreement of NGS were 90%, 90%, and 96.2%, respectively. Following optimization using maximum somatic allele frequency, the sensitivity and specificity of NGS for defining polysomy using plasma samples according to different circulating tumor DNA mutation frequencies were 42% and 63%. The concordance rate between tissue and plasma samples for detecting polysomy was 85%. Regarding the response to MET inhibitor, the median progression-free survival (PFS) of the MET amplification group was significantly higher than that of the polysomy group. The median PFS was similar between the polysomy and normal groups. Our results indicated that NGS may serve as an alternative method for detecting MET polysomy in NSCLC tissues. Moreover, patients with MET polysomy may not benefit from MET inhibitors. SIGNIFICANCE: In this study, we established a methodology to differentiate polysomy from normal copy numbers and amplification using NGS. Moreover, this study suggests that it is critical to discriminate MET polysomy from amplification, for the former may dilute the clinical benefit of MET inhibitors. American Association for Cancer Research 2023-04-04 /pmc/articles/PMC10072163/ /pubmed/37025355 http://dx.doi.org/10.1158/2767-9764.CRC-22-0438 Text en © 2023 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by/4.0/This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.
spellingShingle Research Article
Sun, Boyang
Qiu, Tian
Zeng, Xiaoling
Duan, Jianchun
Bai, Hua
Xu, Jiachen
Li, Jin
Li, Junling
Hao, Xuezhi
Liu, Yutao
Lin, Lin
Wang, Hongyu
Zhang, Xin
Zhong, Jia
Wang, Jie
Ying, Jianming
Wang, Zhijie
Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors
title Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors
title_full Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors
title_fullStr Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors
title_full_unstemmed Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors
title_short Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors
title_sort detection of met polysomy by next-generation sequencing and its clinical relevance for met inhibitors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072163/
https://www.ncbi.nlm.nih.gov/pubmed/37025355
http://dx.doi.org/10.1158/2767-9764.CRC-22-0438
work_keys_str_mv AT sunboyang detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors
AT qiutian detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors
AT zengxiaoling detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors
AT duanjianchun detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors
AT baihua detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors
AT xujiachen detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors
AT lijin detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors
AT lijunling detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors
AT haoxuezhi detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors
AT liuyutao detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors
AT linlin detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors
AT wanghongyu detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors
AT zhangxin detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors
AT zhongjia detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors
AT wangjie detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors
AT yingjianming detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors
AT wangzhijie detectionofmetpolysomybynextgenerationsequencinganditsclinicalrelevanceformetinhibitors